Key result
Concurrent corticosteroid treatment in patients undergoing transfemoral TAVI was associated with a higher rate of minor vascular complications (44% vs 23%; RR 2.65, 95% CI 1.04-6.8, P=0.042).
Why the study?
Does concurrent corticosteroid treatment increase the rate of vascular complications in patients undergoing transfemoral TAVI?
Cohort (n=220)
No
Does concurrent corticosteroid treatment increase the rate of vascular complications in patients undergoing transfemoral TAVI?
Answers are grounded in this paper and cite their sources.
Concurrent corticosteroid treatment in patients undergoing transfemoral TAVI is associated with a significantly increased risk of minor vascular complications.
OBJECTIVE: To assess the rate of Vascular complications in steroid treated patients undergoing transfemoral aortic valve implantation (TAVI). BACKGROUND: Steroid therapy has been associated with increased post-surgical bleeding. Vascular complications are a major concern in patients undergoing TAVI. However, the effect of corticosteroids on vascular complications has not been assessed in these patients. METHODS: We conducted a retrospective analysis of 220 consecutive patients undergoing transfemoral TAVI at our institute between 2009 and 2013. Patients who were on steroids at the time of the procedure (n = 25) were compared with those who were not (n = 195). RESULTS: Baseline characteristics between groups were similar except for greater incidence of chronic renal failure (52 vs. 25%, P = 0.05) and lower left ventricular ejection fraction (50.3 vs. 55.8%, P = 0.037) in the steroid group. The rate of procedural success and nonvascular complication were similar in both groups with the exception of more temporary AV block in the steroid group (24 vs. 8%, P = 0.016). Patients treated with steroids had significantly more minor vascular complication (44 vs. 23%, P = 0.024), and significantly more femoral artery stenosis (16 vs. 5%, P = 0.036), occlusion (8 vs. 1%, P = 0.014), need for femoral artery percutaneous transluminal angioplasty (PTA) (32 vs. 12%, P = 0.009), and femoral artery PTA or stenting (32% vs. 15%, P = 0.031). On multivariate analysis steroid treatment was the only predictor of minor vascular complications (RR=2.65, 95% CI 1.04-6.8, P = 0.042). CONCLUSIONS: Concurrent corticosteroid treatment is associated with a higher rate of minor vascular complication following transfemoral TAVI. Operators should be aware of this risk when assessing patients for the procedure.
No takes yet. Share an insight, caveat, or question.
Fink et al. (2015) conducted a cohort in Transfemoral aortic valve implantation (TAVI) (n=220). Steroid treatment vs. No steroid treatment was evaluated on Minor vascular complications (RR 2.65, 95% CI 1.04-6.8, p=0.042). Concurrent corticosteroid treatment in patients undergoing transfemoral TAVI was associated with a higher rate of minor vascular complications (44% vs 23%; RR 2.65, 95% CI 1.04-6.8, P=0.042).
Synapse has enriched 10 related papers. Consider them for comparative context: